Description: |
This randomized phase III trial is studying docetaxel and leuprolide or goserelin to see how well they work when given before surgery compared with surgery alone in treating patients with high-risk localized prostate cancer. Patients must have histologically confirmed prostate cancer (no small cell, neuro-endocrine, or transitional cell allowed). Patients must have know Gleason sum by biopsy or TURP at registration. Patients must be stage T1-T3a and no radiographic evidence of metastatic disease. They must be deemed high risk by either a) Kattan nomogram predicted probability of being free from biochemical progression at 5 years after surgery of <60% or b) prostate biospy Gleason sum = 8. No prior treatment for prostate cancer, including surgery (except TURP), LN dissection, radiation, or chemotherapy. |
Link: |
Prostate cancer trial for patients with high-risk, clinically localized prostate cancer |
Site: |
George Washington University-Medical Faculty Associates |
Principal Investigator: |
Thomas Jarrett, M.D. |